Mode
Text Size
Log in / Sign up
N/A N=74 Randomized Single-blind Other

Impact of Nicotine Messaging on Beliefs and Behavior

Smoking Behaviors · Cigarette Smoking

Enrolled (actual)
74
Serious AEs
1.9%
Results posted
Dec 2025
Primary outcome: Primary: Nicotine Beliefs — 7.5; 8.1; 5.3; 4.8 score on a scale — p=0.0008

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Nicotine Messaging (Other); Cigarette Condition (Other)
Age
Adult, Older Adult · 21+ yrs
Sex
All
Sponsor
Andrew Strasser
Primary completion
Jun 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Nicotine Beliefs
7.5; 8.1; 5.3; 4.8; 10.8; 10.1 0.0008 sig
SECONDARY
Daily Cigarette Consumption
13.1; 12.5; 13.4; 13.5 0.9804
SECONDARY
Puff Duration
18.3; 21.5; 17.3; 18.4 0.6579
SECONDARY
Carbon Monoxide (CO)
14.9; 12.4; 15.6; 15.8; 5.6; 4.3 0.4208
SECONDARY
Number of Participants With Intention to Use Tobacco/Nicotine Products
3; 1; 5; 1; 4; 2 0.245
SECONDARY
Tobacco Use
30.1; 29.2; 28.4; 29.9 0.6396
SECONDARY
Subjective Cigarette Ratings
61.5; 36.4; 55.1; 36.3; 61.6; 53.2 0.0235 sig

Summary

The purpose of this study is to examine the effect of nicotine messaging and nicotine content of study cigarettes on nicotine beliefs and subsequent use of tobacco and nicotine products.

Eligibility Criteria

Inclusion Criteria

  • Self-report smoking at least 5 non-menthol, filtered cigarettes per day for at least the last 12 months.
  • Not currently undergoing smoking cessation treatment or planning to quit over the duration of the study (~6 weeks).
  • Plan to live in the area for the duration of the study.
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the combined consent and HIPAA form.
  • Able to communicate fluently in English (i.e., speaking, writing, and reading).

Exclusion Criteria

  • Smoke menthol cigarettes greater than 20% of the time.
  • Smoke cigarettes of non-standard circumference (e.g., wides, slim, capri, etc.)
  • Use of any nicotine containing products other than cigarettes. Participants reporting isolated use of other nicotine containing products less than 5 times per month are eligible to participate.
  • Attempt to quit smoking over the duration of the study period.
  • Provide a Carbon Monoxide (CO) reading less than 5 parts per million (ppm) at Session 1 (D0).
  • History of substance abuse (other than nicotine) in the past 12 months and/or currently receiving medical treatment for substance abuse. Attendance at alcoholics anonymous or narcotics anonymous meetings will not be considered medical treatment for the purposes of this protocol.
  • Current alcohol consumption that exceeds 25 standard drinks/week.
  • Women, including all individuals assigned as "female" at birth, who are pregnant, breast feeding, or planning a pregnancy over the duration of the study period.
  • Any impairment including, but not limited to, visual, physical, and/or neurological impairments preventing the proper completion of the study procedures. Notable impairments will be evaluated on a case-by-case basis by the Principal Investigator and/or the Study Physician.
  • Color blindness.
  • Serious or unstable medical condition. Applicable conditions will be evaluated on a case-by-case basis by the Principal Investigator and/or the Study Physician.
  • Lifetime history of schizophrenia, psychosis, and/or bipolar disorder.
  • Current diagnosis of active major depression. Participants who maintain a diagnosis of major depression who have not experienced any major depressive episodes in the past 6 months and are stable on antidepressant medication(s) are eligible to participate.

Additional, general reasons for exclusion include:

  • Past, current, anticipated, or pending enrollment in another research program over the study period that could potentially impact subject safety, study data, and/or the study design as determined by the Principal Investigator and/or Study Physician.
  • Any circumstance, medical condition, illness, disorder, adverse event (AE), or concomitant medication that could compromise participant safety or significantly impact study performance as determined by the Principal Investigator and/or Study Physician. Participants may be withdrawn for any of the aforementioned reasons at any point throughout the study.
  • Significant non-compliance with protocol and/or study design as determined by the Principal Investigator and/or Study Physician. Participants may be withdrawn at any point throughout the study.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05108649). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search